Atrium Therapeutics, Inc. Common Stock (RNA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $162.00M
Last updated: Nov 17, 2026 at 4:20 PM ET
Atrium Therapeutics, Inc. Common Stock (RNA) Stock Chart
Atrium Therapeutics, Inc. Common Stock (RNA) has a latest price of $6.48 on Nov 17, 2026, 61.4% below its 52-week high of $16.77. Its price fell 90.8% over the past 12 months. The month-end price fell 63.2% over the 5 years through Oct 2026, a compound annual decline of 18.1%.
Price Chart
From Jun 2020 to Oct 2026, its highest month-end close was $72.57 in Jan 2026 and its lowest $5.15 in Oct 2023, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart RNA with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for RNA.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price fell 52.7%, and over 6 months it fell 50.0%. The month-end price rose 60.6% over the 3 years through Oct 2026, a compound annual rate of 17.1%.
| Period | Change |
|---|---|
| 1 month | -14.8% |
| 3 months | -52.7% |
| 6 months | -50.0% |
| 12 months | -90.8% |
| 12 months, with dividends | -90.8% |
| Period | Change | Per year |
|---|---|---|
| 3 years | +60.6% | +17.1% |
| 5 years | -63.2% | -18.1% |
Price by Year
Its best calendar year was 2024, when the price rose 221.3%, and its weakest was 2023, when it fell 59.2%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $8.27 | -88.5% |
| 2025 | $72.13 | +148.0% |
| 2024 | $29.08 | +221.3% |
| 2023 | $9.05 | -59.2% |
| 2022 | $22.19 | -6.6% |
| 2021 | $23.77 | -6.9% |
Trading Range
The price is 22.8% below its 50-day average of $8.40 and 61.9% below its 200-day average of $16.99.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $6.48 | |
| 52-week high | $16.77 | -61.4% |
| 52-week low | $6.36 | +1.9% |
| 50-day average | $8.40 | -22.8% |
| 200-day average | $16.99 | -61.9% |
Price Risk
Over 3 years, its largest fall from a peak was 91.2%.
| Measure | Value |
|---|---|
| 1-year beta | 1.38 |
| Largest fall, 1 year | -91.2% |
| Largest fall, 3 years | -91.2% |
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About RNA
What is RNA's 1-year price change?
Atrium Therapeutics, Inc. Common Stock's price fell 90.8% over the past 12 months. With dividends included, the 12-month total return was -90.8%.
What is RNA's 5-year price change?
Atrium Therapeutics, Inc. Common Stock's month-end price fell 63.2% over the 5 years through Oct 2026, a compound annual decline of 18.1%. These figures leave out dividends.
What is RNA's 52-week high and low?
Atrium Therapeutics, Inc. Common Stock's 52-week high is $16.77 and its 52-week low is $6.36. Its latest price of $6.48 on Nov 17, 2026 is 61.4% below the high.
What is RNA's beta?
Atrium Therapeutics, Inc. Common Stock's 1-year beta against the S&P 500 is 1.38, so its price has moved more than the market over the past year. Its largest fall from a peak over the past year was 91.2%.
Is the RNA chart free?
Yes. Advanced Charting for RNA is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
RNA pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors